At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 57 enrolled
Drug / intervention
PL2200 Aspirin Capsules +1 moredrug
Likely dose
PL2200 Aspirin Capsules 325 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)
In Brief
A Phase 3 clinical trial evaluating PL2200 Aspirin Capsules and Enteric-coated aspirin caplets for Diabetes Mellitus, Type 2. Completed, enrolled 57 participants across 3 sites.
Detailed Summary
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric coated aspirin, when administered to patients with diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2014
Primary CompletionApr 2014
TodayJul 2026
First PostedDec 11, 2013
Enrollment StartJan 1, 2014
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.6 years ago
Interventions
PL2200 Aspirin Capsulesdrug
325 mg aspirin; once per day for 10 days
Enteric-coated aspirin capletsdrug
325 mg aspirin; once per day for 10 days